

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 67691

**Title:** The predicting values of BCLC stage subgroup and up-to-7 criteria for therapeutic outcomes to patients with intermediate stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05560824

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Consultant Physician-Scientist, Medical Assistant, Professor, Research Associate

**Reviewer's Country/Territory:** Spain

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2021-05-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-06 06:52

**Reviewer performed review:** 2021-06-06 06:58

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

The available bibliography is limited, it would be advisable to update it with more current bibliography.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 67691

**Title:** The predicting values of BCLC stage subgroup and up-to-7 criteria for therapeutic outcomes to patients with intermediate stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05106340

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2021-05-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-08 05:38

**Reviewer performed review:** 2021-06-08 08:10

**Review time:** 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection

<b>Re-review</b>	[ <input checked="" type="checkbox"/> ] Yes [ <input type="checkbox"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

### SPECIFIC COMMENTS TO AUTHORS

This study aims to determining factors for predicting outcomes of TACE in patients with intermediate stage B HCC. After analysis, the authors found that BCLC stage B HCC patients with smaller tumor size or within up-to-7 criteria had better survival outcomes to TACE. 1) This study assigned 45 solitary HCC patients into BCLC B stage. Please give the reason of staging. 2) Any complications as liver faliure for TACE? 3) How many cases were treated with TACE followed by surgery if any? 4) The authors can show that patients with smaller tumor size or within up-to-7 criteria had better survival outcomes to TACE. This is interesting and important to know. I miss a detailed discussion why the authors think that especially these patients/tumors benefit (difference to beyond up-to-7 criteria, larger tumor ...). 5) There are similar studies that predicting outcomes of TACE (J Hepatol, 2019,70(5):893-903 and Eur radiol 2020,30(4):2365-2376). How about the discrimination degree when compare the up-to-7 criteria and other criteria such as Milan criterion or other similar studies. 6) There are mistakes in the line 1 of result of Abstract (non-OR group), and page 10 (BLCC).